Palatin Technologies (PTN) Stock Price, News & Analysis

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Key Stats

• Today's Range: $1.05 to $1.12
• 50-Day Range: N/A
• 52-Week Range: $0.68 to $5.65
• Volume: 227,132 shs
• Average Volume: 361,969 shs
• Market Capitalization: $21.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Buy

Palatin Technologies Stock Analysis - MarketRank™

Palatin Technologies scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Palatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Palatin Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Palatin Technologies is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palatin Technologies is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.04% of the float of Palatin Technologies has been sold short.

Short Interest Ratio / Days to Cover

Palatin Technologies has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Palatin Technologies has recently decreased by 5.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palatin Technologies does not currently pay a dividend.

Dividend Growth

Palatin Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.04% of the float of Palatin Technologies has been sold short.

Short Interest Ratio / Days to Cover

Palatin Technologies has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Palatin Technologies has recently decreased by 5.01%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Palatin Technologies has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Palatin Technologies this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

8 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Palatin Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.10% of the stock of Palatin Technologies is held by insiders.

Percentage Held by Institutions

Only 11.50% of the stock of Palatin Technologies is held by institutions.

PTN Stock Analysis - Frequently Asked Questions

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings data on Wednesday, May, 15th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.03.

When did Palatin Technologies' stock split?

Shares of Palatin Technologies reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Palatin Technologies' major shareholders?

Top institutional shareholders of Palatin Technologies include HB Wealth Management LLC (0.57%). Insiders that own company stock include Stephen T Wills, Alan W Dunton and Robert K Deveer Jr.
View institutional ownership trends.

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Palatin Technologies investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), 22nd Century Group (XXII), NightHawk Biosciences (NHWK), NVIDIA (NVDA) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/15/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 2/12/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:PTN
• Previous Symbol: NYSE:PTN
• CUSIP: N/A
• CIK: 911216
• Web: www.palatin.com
• Phone: (609) 495-2200
• Fax: 609-495-2202
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.00
• High Stock Price Target: $17.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +1,459.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,740,000.00
• Net Margins: N/A
• Pretax Margin: -1,590.66%
• Return on Equity: N/A
• Return on Assets: -334.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.26
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: $4.49 million
• Price / Sales: 4.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: -109.00

Miscellaneous

• Outstanding Shares: 19,550,000
• Free Float: 18,160,000
• Market Cap: $21.31 million
• Optionable: Not Optionable
• Beta: 0.90